LMRI:NASDAQLumexa Imaging Holdings, Inc. Analysis

Lumexa Imaging (LMRI) trades at $6.77, well below its 20‑day SMA of 9.31 and 50‑day SMA of 10.10, indicating a bearish price trend, while the RSI of 28 suggests the stock is oversold. The technical picture is mixed: MACD is bearish, but the support level sits at 6.45 with a sizable upside potential of 178 % to the median analyst target of $19. Fundamentals show a forward P/E of 7.13, far under the industry average of 26.86, and a price‑to‑book of 1.11, implying the market may be undervaluing the business. However, the company carries a heavy debt load (debt‑to‑equity > 160) and posted a negative profit margin of -3.66 %, raising concerns about cash generation and leverage. Recent news highlights the appointment of Kyle Lynch to the executive team and guidance for FY2026 revenue of $1.045‑$1.097 B with plans for 8‑10 new de‑novo centers, which could drive top‑line growth. Operating cash flow remains modest at $33.9 M and free cash flow is flat, underscoring the need for disciplined capital allocation. With a beta of 2.42 and 30‑day volatility near 98 %, price swings are likely to be pronounced, demanding caution despite the strong “strong buy” analyst consensus.